Israel-based Teva Pharmaceutical Industries Ltd (NYSE and TASE: TEVA) has launched a generic version of VESIcare (solifenacin succinate) Tablets, 5mg and 10mg, in the United States, it was reported yesterday.

The products are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Solifenacin Succinate Tablets are contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug.

VESIcare Tablets have annual sales of more than USD955m in the US, according to IQVIA data as of February 2019.